Biotest AG / Key word(s): Preliminary Results 11.02.2016 08:29 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad-hoc RELEASE Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest exceeds EBIT guidance for 4th quarter 2015 Dreieich, 11. February 2016. According to preliminary and unaudited figures, the Biotest Group exceeds its EBIT guidance published in November 2015 in the amount of EUR 5-10 million for the fourth quarter 2015 and reports an EBIT of EUR 10.2 million in the fourth quarter 2015. The revenues came in at EUR 171.7 million, which is on the previous year's level of EUR 172.1 million. According to preliminary and unaudited figures, the Biotest Group increased revenues in the full year 2015 to EUR 589.6 million. This represents an increase of 1.3 % compared to the previous year (2014: EUR 582.0 million). On account of an unscheduled write down and impairment in the third quarter 2015 in the amount of EUR 84 million and the termination of the cooperation with AbbVie the preliminary and unaudited Group's earnings before interest and tax (EBIT) stand at - EUR 72.3 million (2014: EUR 53.4 million). Biotest will publish final results for the Financial Year 2015 and the annual report on March 23rd, 2016. Biotest Aktiengesellschaft Board of Management Biotest AG Landsteinerstr. 5 D-63303 Dreieich www.biotest.de Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and Systemic lupus erythomatosus, which are produced by recombinant technologies. Biotest has more than 2.200 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange. Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 Securities' ID No., ISIN preference shares: 522723, DE0005227235 Listing: Prime Standard Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart 11.02.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Biotest AG: Biotest exceeds EBIT guidance for 4th quarter 2015
| Source: EQS Group AG